循环血浆外泌体PD-L1预测头颈部鳞状细胞癌放疗后预后
这项回顾性观察研究分析了76例接受放疗的头颈部鳞状细胞癌患者放疗前血浆样本,中位随访32.5个月。血浆外泌体PD-L1高表达患者的1年无进展生存率和1年局部控制率均显著低于低表达患者,且外泌体PD-L1是无进展生存和局部控制的预后因素,但对总生存无显著影响。
要点
- 血浆外泌体PD-L1高表达患者1年无进展生存率为33.3%,低表达者为79.2%(P < .001)。
- 血浆外泌体PD-L1高表达患者1年局部控制率为50.0%,低表达者为87.3%(P < .001)。
- 血浆外泌体PD-L1对总生存无显著影响,总PD-L1与无进展生存、局部控制和总生存均不相关。
核心结论
- 头颈部鳞状细胞癌患者放疗前循环血浆外泌体PD-L1是放疗后的预后因素。
研究设计与样本
- 回顾性观察研究,纳入2019年6月至2021年8月接受放疗的76例头颈部鳞状细胞癌患者,分析放疗前血浆样本,中位随访32.5个月。
主要发现
- 血浆总PD-L1中位浓度为115.1 pg/mL(95% CI,114.7-137.9 pg/mL),外泌体PD-L1中位浓度为2.8 pg/mL(95% CI,6.0-13.0 pg/mL)。
- 单因素和多因素分析显示外泌体PD-L1是无进展生存和局部控制的预后因素。
- 外泌体PD-L1高表达患者1年无进展生存率为33.3%,低表达患者为79.2%(P < .001)。
- 外泌体PD-L1高表达患者1年局部控制率为50.0%,低表达患者为87.3%(P < .001)。
- 血浆外泌体PD-L1对总生存无显著影响,血浆总PD-L1与无进展生存、局部控制和总生存均不相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Radiation therapy is widely used to treat head and neck squamous cell carcinoma (HNSCC). This study evaluated the association between circulating plasma programmed death-ligand 1 (PD-L1) and the outcomes of patients with HNSCC after radiation therapy. METHODS AND MATERIALS: In this retrospective observational study, plasma samples of 76 patients with HNSCC who underwent radiation therapy from June 2019 to August 2021 were analyzed. These plasma samples were obtained before radiation therapy. The median follow-up was 32.5 months. Total and exosomal PD-L1 was measured by enzyme-linked immunosorbent assay and retrospectively analyzed for association with overall survival (OS), progression-free survival (PFS), and local control (LC). Prognostic factors among patients' characteristics and circulating PD-L1 in plasma were evaluated by univariate (log-rank test) and multivariate (Cox proportional hazards model) analyses. RESULTS: The median concentration of total PD-L1 in plasma was 115.1 pg/mL (95% CI, 114.7-137.9 pg/mL), and the median concentration of exosomal PD-L1 was 2.8 pg/mL (95% CI, 6.0-13.0 pg/mL). Univariate and multivariate analyses showed exosomal PD-L1 as a prognostic factor for PFS and LC. Patients with high exosomal PD-L1 in plasma had poor PFS and LC compared with those with low exosomal PD-L1, indicating that 1-year PFS was 79.2% versus 33.3% (P < .001) and 1-year LC was 87.3% versus 50.0% (P < .001) in patients with high and low exosomal PD-L1, respectively. However, exosomal PD-L1 in plasma had no significant effect on OS. Total PD-L1 in plasma did not correlate with PFS, LC, and OS. CONCLUSIONS: The pretreatment circulating exosomal PD-L1 in plasma of patients with HNSCC was a prognostic factor after radiation therapy.
引用
- Tamari K, Minami K, Tatekawa S, et al. Circulating Plasma Exosomal PD-L1 Predicts Prognosis of Head and Neck Squamous Cell Carcinoma After Radiation Therapy. Adv Radiat Oncol. 2023. PMID: 38405303. doi:10.1016/j.adro.2023.101353
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。